Physician profile
Mikala Ramirez
NPI 1851969877
$1,281.62
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $187 · 2022: $219 · 2023: $528 · 2024: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $856 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $855.50 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $237.90 | 2021-2024 | |
| Novo Nordisk INC | $188.22 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $129.40 | 2022-2023 | |
| Axsome Therapeutics, INC. | $112.38 | 2023-2024 | Auvelity |
| Exact Sciences Corporation | $80.87 | 2023-2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $74.69 | 2023-2024 | Voquezna |
| Lilly USA, LLC | $68.49 | 2022-2023 | Jardiance |
| Idorsia Pharmaceuticals US INC | $49.73 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $48.23 | 2023 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.90 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $35.90 | 2023-2024 | Farxiga, Airsupra |
| Astellas Pharma US INC | $34.48 | 2022-2023 | Myrbetriq |
| Esperion Therapeutics, INC. | $30.01 | 2023 | Nexletol |
| Smith+Nephew, INC. | $21.69 | 2021 | |
| Sumitomo Pharma America, INC. | $19.00 | 2024 | Gemtesa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $17.72 | 2023 | |
| Pfizer INC. | $17.67 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2021 | |
| Seqirus USA INC | $14.56 | 2024 | Fluad, Flucelvax |
| Supernus Pharmaceuticals, INC. | $13.75 | 2021 | |
| Ironwood Pharmaceuticals, INC | $13.74 | 2024 | |
| Merck Sharp & Dohme LLC | $12.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikala Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.